NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis → This TSLA short trade is on a nine win hot streak (From WealthPress) (Ad) Free MOR Stock Alerts $18.39 +0.03 (+0.16%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$18.29▼$18.4150-Day Range$17.36▼$19.3452-Week Range$4.18▼$19.50Volume60,339 shsAverage Volume1.42 million shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$11.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get MorphoSys alerts: Email Address MorphoSys MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside35.9% Downside$11.78 Price TargetShort InterestBearish1.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.43) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.10 out of 5 starsMedical Sector925th out of 929 stocksPharmaceutical Preparations Industry438th out of 438 stocks 1.1 Analyst's Opinion Consensus RatingMorphoSys has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphoSys has only been the subject of 1 research reports in the past 90 days.Read more about MorphoSys' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.18% of the outstanding shares of MorphoSys have been sold short.Short Interest Ratio / Days to CoverMorphoSys has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in MorphoSys has recently increased by 41.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphoSys does not currently pay a dividend.Dividend GrowthMorphoSys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOR. Previous Next 1.8 News and Social Media Coverage News SentimentMorphoSys has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MorphoSys this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for MOR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MorphoSys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of MorphoSys is held by insiders.Percentage Held by InstitutionsOnly 18.38% of the stock of MorphoSys is held by institutions.Read more about MorphoSys' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MorphoSys are expected to grow in the coming year, from ($2.43) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MorphoSys is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MorphoSys is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MorphoSys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StockWireNewsDiscover little-known stocks with HUGE potential to soar in 2024Imagine having the power to identify stocks that are flying under the radar, yet hold the potential to deliver jaw-dropping returns. Identifying these hidden gems before they go mainstream can be a game-changer for you. Claim your free Wealth Building Report by clicking here now. About MorphoSys Stock (NASDAQ:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesMay 28 at 7:52 PM | msn.comMonoclonal Antibody May Benefit Patients With Kidney Transplant RejectionMay 27, 2024 | msn.comNovartis releases Phase III data on its investigational oral therapy to treat chronic kidney diseaseMay 16, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | finance.yahoo.comNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 16, 2024 | markets.businessinsider.comNovartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash DealMay 16, 2024 | globenewswire.comNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashMay 10, 2024 | finance.yahoo.comMorphoSys (ETR:MOR) shareholders have earned a 228% return over the last yearMay 6, 2024 | finance.yahoo.comMorphoSys AG (MOR2.DU)April 29, 2024 | msn.comMorphoSys reports Q1 resultsApril 29, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports First Quarter 2024 Financial ResultsApril 29, 2024 | uk.investing.comMorphosys says takeover by Novartis on course after report of drug safety concernApril 29, 2024 | benzinga.comMorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, PelabresibApril 29, 2024 | reuters.comMorphosys says Novartis takeover progressing as planned for H1 2024April 28, 2024 | markets.businessinsider.comHere's what to expect from Morphosys's earningsApril 27, 2024 | msn.comGermany stocks higher at close of trade; DAX up 1.39%April 23, 2024 | ca.finance.yahoo.comNovartis lifts guidance after Q1 results beat expectationsApril 23, 2024 | uk.finance.yahoo.comNovartis raises guidance after beating Q1 expectationsApril 11, 2024 | markets.businessinsider.comEQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | markets.businessinsider.comMorphoSys Recommends Shareholders Accept Offer By Novartis - Quick FactsApril 11, 2024 | finance.yahoo.comMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | businesswire.comMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | finanznachrichten.deAspermont Limited: Aspermont is Announcing 'Future of Mining Perth': Unveiling Innovations, Sustainability, and Industry Growth!April 11, 2024 | reuters.comNovartis begins tender offer for MorphoSysApril 11, 2024 | globenewswire.comNovartis tender offer for MorphoSys AG commencesMarch 20, 2024 | investing.comMorphoSys AG ADR (MOR)See More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today5/31/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MOR CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees524Year FoundedN/APrice Target and Rating Average Stock Price Target$11.78 High Stock Price Target$18.25 Low Stock Price Target$4.75 Potential Upside/Downside-35.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,350,000.00 Net Margins-226.79% Pretax Margin-225.77% Return on Equity-694.31% Return on Assets-22.55% Debt Debt-to-Equity Ratio4.98 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$257.89 million Price / Sales10.74 Cash FlowN/A Price / Cash FlowN/A Book Value($1.89) per share Price / Book-9.73Miscellaneous Outstanding Shares150,620,000Free Float150,546,000Market Cap$2.77 billion OptionableNot Optionable Beta1.15 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.91MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $764.53kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $513.54kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVElanco Animal HealthNYSE:ELANAscendis Pharma A/SNASDAQ:ASNDLegend BiotechNASDAQ:LEGNView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Sold 80,000 shares on 5/29/2024Ownership: 0.043%Carlson Capital L PBought 950,461 shares on 5/14/2024Ownership: 0.631%Henry James International Management Inc.Bought 45,506 shares on 5/8/2024Ownership: 0.059%Susquehanna International Group Ltd.Bought 73,477 shares on 5/7/2024Ownership: 0.049%SAL Trading LLCBought 26,800 shares on 5/7/2024Ownership: 0.018%View All Institutional Transactions MOR Stock Analysis - Frequently Asked Questions Should I buy or sell MorphoSys stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares. View MOR analyst ratings or view top-rated stocks. What is MorphoSys' stock price target for 2024? 7 Wall Street analysts have issued 1-year target prices for MorphoSys' stock. Their MOR share price targets range from $4.75 to $18.25. On average, they anticipate the company's share price to reach $11.78 in the next year. This suggests that the stock has a possible downside of 35.9%. View analysts price targets for MOR or view top-rated stocks among Wall Street analysts. How have MOR shares performed in 2024? MorphoSys' stock was trading at $9.90 on January 1st, 2024. Since then, MOR shares have increased by 85.8% and is now trading at $18.39. View the best growth stocks for 2024 here. Are investors shorting MorphoSys? MorphoSys saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,770,000 shares, an increase of 41.6% from the April 30th total of 1,250,000 shares. Based on an average trading volume of 431,000 shares, the short-interest ratio is presently 4.1 days. View MorphoSys' Short Interest. When is MorphoSys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our MOR earnings forecast. How were MorphoSys' earnings last quarter? MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings results on Monday, April, 29th. The company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $1.73. The company had revenue of $29.86 million for the quarter, compared to analyst estimates of $48.99 million. MorphoSys had a negative net margin of 226.79% and a negative trailing twelve-month return on equity of 694.31%. What ETFs hold MorphoSys' stock? ETFs with the largest weight of MorphoSys (NASDAQ:MOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What is Simon E. Moroney's approval rating as MorphoSys' CEO? 5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. Who are MorphoSys' major shareholders? MorphoSys' stock is owned by many different retail and institutional investors. Top institutional shareholders include Carlson Capital L P (0.63%), Hennion & Walsh Asset Management Inc. (0.08%), Henry James International Management Inc. (0.06%), Susquehanna International Group Ltd. (0.05%), Susquehanna International Securities Ltd. (0.05%) and Opaleye Management Inc. (0.04%). How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MOR) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.